These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 35167789

  • 1. Nephrogenic Systemic Fibrosis in the Setting of Transient Renal Insufficiency.
    Dinh H, Phan J, Lountzis NI, Purcell SM.
    Cutis; 2021 Dec; 108(6):342-344. PubMed ID: 35167789
    [Abstract] [Full Text] [Related]

  • 2. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
    Mundim JS, Lorena Sde C, Abensur H, Elias RM, Moysés RM, Castro MC, Romão Júnior JE.
    Rev Assoc Med Bras (1992); 2009 Dec; 55(2):220-5. PubMed ID: 19488662
    [Abstract] [Full Text] [Related]

  • 3. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.
    Bernstein EJ, Schmidt-Lauber C, Kay J.
    Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):489-503. PubMed ID: 23040363
    [Abstract] [Full Text] [Related]

  • 4. Ocular pathologic features and gadolinium deposition in nephrogenic systemic fibrosis.
    Barker-Griffith A, Goldberg J, Abraham JL.
    Arch Ophthalmol; 2011 May; 129(5):661-3. PubMed ID: 21555622
    [No Abstract] [Full Text] [Related]

  • 5. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR, Pedersen M, Jørgensen B, Søndergaard K, Jensen JD, Ramsing M, Olesen AB.
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [Abstract] [Full Text] [Related]

  • 6. Current status of nephrogenic systemic fibrosis.
    Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H.
    Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
    [Abstract] [Full Text] [Related]

  • 7. Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.
    Larson KN, Gagnon AL, Darling MD, Patterson JW, Cropley TG.
    JAMA Dermatol; 2015 Oct; 151(10):1117-20. PubMed ID: 26017458
    [Abstract] [Full Text] [Related]

  • 8. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD, Bernheisel CR.
    Am Fam Physician; 2009 Oct 01; 80(7):711-4. PubMed ID: 19817341
    [Abstract] [Full Text] [Related]

  • 9. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J.
    Ann Rheum Dis; 2008 Dec 01; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [Abstract] [Full Text] [Related]

  • 10. Time-dependent decrement of dermal gadolinium deposits and significant improvement of skin symptoms in a patient with nephrogenic systemic fibrosis after temporary renal failure.
    Schäd SG, Heitland P, Kühn-Velten WN, Gross GE, Jonas L.
    J Cutan Pathol; 2013 Nov 01; 40(11):935-44. PubMed ID: 24102613
    [Abstract] [Full Text] [Related]

  • 11. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network.
    Stratta P, Canavese C, Quaglia M, Fenoglio R.
    Rheumatology (Oxford); 2010 Apr 01; 49(4):821-3. PubMed ID: 20032228
    [No Abstract] [Full Text] [Related]

  • 12. [Nephrogenic systemic fibrosis: a rare disease with grave consequences].
    Kielstein JT, Schiffer M.
    Internist (Berl); 2010 Jan 01; 51(1):39-44. PubMed ID: 20033388
    [Abstract] [Full Text] [Related]

  • 13. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN.
    Radiographics; 2009 Oct 01; 29(6):1565-74. PubMed ID: 19959508
    [Abstract] [Full Text] [Related]

  • 14. Nephrogenic systemic fibrosis.
    Weinreb JC, Kuo PH.
    Magn Reson Imaging Clin N Am; 2009 Feb 01; 17(1):159-67. PubMed ID: 19364606
    [Abstract] [Full Text] [Related]

  • 15. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.
    Penfield JG.
    Pediatr Nephrol; 2008 Dec 01; 23(12):2121-9. PubMed ID: 18543004
    [Abstract] [Full Text] [Related]

  • 16. Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.
    Alfano G, Fontana F, Ferrari A, Solazzo A, Perrone R, Giaroni F, Torricelli P, Cappelli G.
    Magn Reson Imaging; 2020 Jul 01; 70():1-4. PubMed ID: 32112811
    [Abstract] [Full Text] [Related]

  • 17. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC, Abu-Alfa AK.
    J Magn Reson Imaging; 2009 Dec 01; 30(6):1236-9. PubMed ID: 19938035
    [Abstract] [Full Text] [Related]

  • 18. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
    Natalin RA, Prince MR, Grossman ME, Silvers D, Landman J.
    J Urol; 2010 Jan 01; 183(1):27-33. PubMed ID: 19913804
    [Abstract] [Full Text] [Related]

  • 19. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
    Varela CU, Prieto-Rayo JC.
    Rev Med Chil; 2014 Dec 01; 142(12):1565-74. PubMed ID: 25693439
    [Abstract] [Full Text] [Related]

  • 20. [Nephrogenic fibrosing dermatosis: From clinic to microscopy].
    Yoldez H, Ahlem B, Abderrahim E, Faten Z, Soumaya R.
    Nephrol Ther; 2018 Feb 01; 14(1):47-49. PubMed ID: 29239786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.